We describe a novel imaging method to assess central nervous system pathology called "Diffusion Basis Spectrum Imaging" (DBSI). Diffusion tensor imaging (DTI) has been widely used to estimate axonpathology and demyelination. However, in the settings of acute inflammation and chronic tissue loss asare common in multiple sclerosis, DTI signals can lead to false interpretations. DBSI is a computationallynovel method that separates isotropic from anisotropic components in imaging voxels. Isotropicdiffusion is believed to reflect inflammatory components (cells, edema), as well as intrinsic cells andextracellular space. DBSI enables the measurement of axial and radial diffusivities within the anisotropiccomponents of imaging voxels, which reflect the integrity of axon fibers and myelin, respectively.
Introduction
Multiple sclerosis (MS) is a chronic disease of complex and heterogeneous pathology which involves inflammation, demyelination, remyelination and axon injury and loss. MS is common -about 2.5 million people worldwide have the disease. The pathology of MS varies between individuals and in the same individual patient over the time-course of the disease (Lucchinetti et al., 2000) . The variability of the clinical course and neuropathology of MS has proven to be a barrier to the complete understanding of the disease. As biopsies of the central nervous system (CNS) are infrequent (and are usually done in atypical cases) and serial biopsies are even more rarely done, understanding of the underlying neuropathology of MS derives mainly from end-of-life autopsies and less invasive methods such as imaging and blood and cerebrospinal fluid (CSF) analyses. Methods providing a non-invasive window into the CNS to better understand the pathophysiology of progression are greatly needed.
Inflammatory demyelination of CNS white matter (WM) was formerly regarded as the main pathology of MS. Prior to the past two decades, gray matter (GM) involvement received less emphasis which is perhaps due to the difficulty to detect or measure it. However GM involvement in MS, including cortical GM damage, can be extensive and correlates better with disability measures than does WM damage (Fisher et al., 2008; Rudick et al., 2009 ). The primary substrate of disability is thought to be axon injury and loss (Kornek et al., 2001) . Accurate measures of axon injury and loss in the CNS of MS patients are needed to better understand the pathology of MS over the course of the disease, to monitor responses to therapies, and to use as a surrogate marker in clinical trials, especially for progressive MS trials.
The advent of magnetic resonance imaging (MRI) revolutionized the diagnosis and has greatly improved the monitoring of MS. Gadoliniumenhanced MRI lesions serve as surrogate biomarkers of clinical MS relapses (Sormani et al., 2009) . The latter has expedited research leading to approval of several of the thirteen disease modifying therapies (DMTs) for relapsing forms of MS. Current DMTs work best to reduce relapse rate, but do not completely eliminate relapses, and do not work in all patients. None of the present approved DMTs are highly effective at slowing disability progression and none yet repairs axons in the CNS. Novel imaging tools that can be used to identify responses to promising new therapies, such as remyelinating agents that are in early phases (Mi et al., 2013; Wootla et al., 2013) are also needed. This paper will discuss updates on diffusion MR methods to detect and quantitate axon loss, as well as demyelination, cellular inflammation and edema in the MS-affected CNS.
Diffusion magnetic resonance imaging
Diffusion-weighted MRI measures water apparent diffusion coefficient (ADC) through the application of a pair of diffusion weighting pulsed magnetic field gradients of altering magnitude, duration, and time interval of separation between gradients; the term "b-value" derived from a landmark study (Stejskal & Tanner, 1965 ) is used to control
